Wednesday, September 26, 2012

Yukon-Nevada Gold,YNG,YNGFF, Profile, Summary

Yukon-Nevada Gold| YNG |YNGFF | Profile | Summary

Yukon-Nevada Gold Corp is listed on the Toronto Stock Exchange (YNG.TO)
and trades on the OTC/Pinksheets under the symbol YNGFF.

Jerritt Canyon, the Company's flagship project, is located in northern Nevada. The Company is currently focused on modernizing the milling facility and emission control systems. The Company is striving to reach a point of renewed profitability accompanied by a significantly reduced environmental impact. Ongoing permitting at Starvation Canyon, Nevada will allow the Company, in the future, to realize an increase in the production of gold ounces at Jerritt Canyon.

The Company is focused on bringing its wholly owned Ketza River property back into production from the Manto Gold Zones and permitting is underway. The Ketza River Property includes the Ketza River mine, which, from 1987 to 1990, produced 98,000 oz of gold and by-product silver from 340,000 tons of ore.


    1. Jerritt Canyon - historical production of approximately 8 million oz gold since 1981
+ 100% owned.
+ Permitted and Producing.
+ Current Reserve & Resource includes: 374,800 oz Proven, 686,000 oz Probable, 1.03M oz Measured & 1.29M oz Indicated.
+ Mill engineered capacity of 6,000 tpd of which 5,280 tpd is currently permitted.

    2. Ketza River - historical production of 98,000 oz of gold and by-product silver between 1988 - 1990
+ 100% owned.
+ Current Resource includes: 29,000 oz Measured and 388,700 oz Indicated.
+ Site infrastructure well developed.
+ Permitting in progress for mine/mill re-start.

Deutsche Bank invested $40M in equity and $140M gold forward sale.


Planned mine includes 9 open pits and
2 underground declines

+ 83% of the oz to be mined will come from the open pits.
+ Estimated mining rate of 50,000 tpd for the first 2 years and 20,000 tpd in the 3rd year from the open pits.
+ An additional 500 tpd will come from underground mining.

A total of 41% of the measured and indicated recoverable resource ounces are hosted in oxide ores which have a gold recovery of 90%; whereas the other 59% of the measured and indicated recoverable, resource ounces are hosted in sulfide or mixed sulfide+oxide ores that generally have Au recoveries of 70%.

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoneywe received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Saturday, September 8, 2012

HOKU, Hoku Corporation, Profile, Summary

Hoku Corporation | HOKU | Profile | Summary
Hoku Corporation (HOKU) is a solar products and services company operating two businesses: Hoku Materials and Hoku Solar. Hoku Materials manufactures, markets and sells polysilicon for the solar industry from its plant currently under construction in Pocatello, Idaho. Hoku Solar is a leading provider of commercial solar power, offering turnkey PV systems and project development services.

Hoku Solar
Hoku Solar – HOKU - is a leading provider of investment-grade solar power, offering project development services, turnkey PV system integration and asset management for solar energy facilities.
Hoku Solar focuses primarily on the commercial and industrial solar market segment, providing large-scale rooftop or ground-mounted PV arrays for businesses, institutions and government clients. We have proven experience with specialty and technical solar products, including third party financed purchase power agreements (PPAs), and building integrated PV. Hoku is also increasingly engaged in the multi-megawatt utility scale market, both as a project developer and as an EPC service provider.
Hoku Solar is active in Hawaii, and is expanding its project development business to other U.S. markets.
Hoku Solar Services

Turnkey PV Integration
Hoku Solar is a full-service solar industry EPC contractor, providing its customers with turnkey engineering, procurement, and construction services for investment-grade PV.

Hoku Solar primarily serves commercial and industrial rooftop customers, large real estate portfolio holders and developers, general contractors, and government and institutional clients.

With proven experience in the Hawaii market, Hoku can deliver a full range of commercial systems, ranging from individual rooftop arrays to multi-megawatt ground-mounted systems.
Project Development
With our unique design and development service offering, Hoku Solar is positioned to bring large-scale and portfolio PV projects to life, whether as lead developer, or as a complement to an existing project team.
Hoku Solar has proven experience at every stage of the PV development cycle – from feasibility studies to commissioning and take-out financing – and we tailor our services to the individual needs of the project. So, whether Hoku is leading the development itself, or contributing to a broader effort, we are focused on scaling up solar in the U.S.
Contact us today and let us put our experience to work for you.
Asset Management
Underperforming solar arrays are underperforming investments. Hoku Solar has the engineering, technical and operational experience to help ensure your target returns are achieved.

We offer customized operations and maintenance programs for a wide variety of commercial systems, each designed to enhance overall system performance and reliability. From system assessment to preventative and corrective maintenance and monitoring, let Hoku Solar’s asset management team help guarantee your PV system’s long-term performance.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have any questions, please don't hesitate to contact the Editor [@ ] OxBridgeResearch.com

Sunday, September 2, 2012

Romney's Tax Secret Revealed! How to Convert Ordinary Income into Capital Gains.

The New York attorney general is investigating whether some of the nation’s biggest private equity firms have abused a tax strategy in order to slice hundreds of millions of dollars from their tax bills, according to executives with direct knowledge of the inquiry.
Enlarge This Image

Andrew Harrer/Bloomberg News
The Washington office of the Carlyle Group, which The Carlyle Group has stated in regulatory filings that their partners have not diverted management fees into investments in their funds.
Enlarge This Image

Evan McGlinn for The New York Times
Bain offices in Boston. According to financial statements, Bain partners saved more than $200 million in federal income taxes and more than $20 million in Medicare taxes.
Readers’ Comments
Share your thoughts.
Post a Comment »
Read All Comments (218) »
The attorney general, Eric T. Schneiderman, has in recent weeks subpoenaed more than a dozen firms seeking documents that would reveal whether they converted certain management fees collected from their investors into fund investments, which are taxed at a far lower rate than ordinary income.
Among the firms to receive subpoenas are Kohlberg Kravis Roberts & Company, TPG Capital, Sun Capital Partners, Apollo Global Management, Silver Lake Partners and Bain Capital, which was founded by Mitt Romney, the Republican nominee for president. Representatives for the firms declined to comment on the inquiry.
Mr. Schneiderman’s investigation will intensify scrutiny of an industry already bruised by the campaign season, as President Obama and the Democrats have sought to depict Mr. Romney through his long career in private equity as a businessman who dismantled companies and laid off workers while amassing a personal fortune estimated at $250 million.
Some executives at the firms said they feared that Mr. Schneiderman, a first-term Democrat with ties to the Obama administration, was seeking to embarrass the industry because of Mr. Romney’s roots at Bain. Others suggested that the subpoenas, which were issued by the attorney general’s Taxpayer Protection Bureau, might be part of an effort to recover more revenue for New York under state tax law. The attorney general’s office does not have the power to enforce federal tax laws.
A spokesman for Mr. Schneiderman declined to comment.
The tax strategy — which is viewed as perfectly legal by some tax experts, aggressive by others and potentially illegal by some — came to light last month when hundreds of pages of Bain’s internal financial documents were made available online. The financial statements show that at least $1 billion in accumulated fees that otherwise would have been taxed as ordinary income for Bain executives had been converted into investments producing capital gains, which are subject to a federal tax of 15 percent, versus a top rate of 35 percent for ordinary income. That means the Bain partners saved more than $200 million in federal income taxes and more than $20 million in Medicare taxes.
The subpoenas, which executives said were issued in July, predated the leak of the Bain documents by several weeks and do not appear to be connected with them. Mr. Schneiderman, who is also co-chairman of a mortgage fraud task force appointed by Mr. Obama, has made cracking down on large-scale tax evasion a priority of his first term.
As a retired partner, Mr. Romney continues to receive profits from Bain Capital and has had investments in some of the funds that documents show used the tax strategy.
The campaign issued a statement saying that Mr. Romney did not, however, benefit from the practice. “Investing fee income is a common, accepted and totally legal practice,” said R. Bradford Malt, a lawyer for Mr. Romney who manages his family’s investments and trusts. “However, Governor Romney’s retirement agreement did not give the blind trust or him the right to do this, and I can confirm that neither he nor the trust has ever done this, whether before or after he retired from Bain Capital.”
Managers at a typical private equity firm or hedge fund collect from their investors management fees based on the size of the fund. But most of their compensation comes as a share of the profits earned by the fund. The Internal Revenue Service allows those profits to be considered “carried interest,” taxed at the capital gains rate typically reserved for investments.
The tax strategy used by Bain and other firms to convert management fees — the compensation normally taxed as ordinary income — into capital gains is known as a “management fee waiver.” The strategy is widely used within the industry: 40 percent of the 35 buyout firms based in the United States surveyed in 2009 by Dow Jones said their partners used at least some of the firm’s fees to make investments in their funds.
But some prominent firms appear to avoid the practice. The Carlyle Group and Blackstone Group have stated in regulatory filings that their partners have not diverted management fees into investments in their funds.
In the varied world of private equity, some firms may have lawyers who are not aware of the strategy or have steered their clients away from it, said a lawyer at one firm who has used the strategy for his clients. Others, he said, may not have the operational capabilities to handle the complex transactions.
Apollo Global Management, the buyout firm co-founded by Leon Black and now publicly traded, is among those that use the conversion strategy. Between 2007 and 2011, Apollo converted more than $131 million in fees into investments in its funds, according to S.E.C. filings. A spokesman for the firm declined to comment.
Likewise, K.K.R. converted more than $180 million in fees between 2007 and 2009, according to its filings. Kristi Huller, a spokeswoman for the firm, declined to comment about any regulatory matter, but said in an e-mail that K.K.R. had not used the tax strategy “for the past few years.”
Other firms that received subpoenas include Clayton, Dubilier & Rice; Crestview Partners; H.I.G. Capital; Vestar Capital Partners; and Providence Equity Partners. Representatives for all these firms declined to comment.
Tax lawyers have justified the arrangements by arguing that converting the management fees into carried interest, which could lose some or all of its value if a fund does poorly, entitles the managers to the lower capital gains rate, which is intended to help mitigate the risks taken by investors.
“They’re risking their management fee — they’re giving up the right to that management fee in any and all events,” said Jack S. Levin, a finance lawyer whose firm has represented Bain on some matters. Mr. Levin said he did not consider the practice risky or even aggressive.
“The I.R.S. has known that private equity funds have been doing this for 20 years,” he said.
In 2007, the agency began taking a closer look at suspected tax abuses at hedge funds and private equity firms. In a statement at the time, an I.R.S. spokesman said that management fee conversions were among several “areas of possible noncompliance.” But no formal ruling appears to have emerged.
Some private equity firms take what tax experts consider a less aggressive approach to the conversions, waiving fees on all of a given fund’s investments over the lifetime of the fund, which can be 10 years.
But other firms choose which funds or even which particular investments to waive fees on frequently, like every year or every quarter. Such arrangements may allow the executives to apply the waiver only when they believe their funds are more likely to appreciate in value, substantially reducing their investment risk.
Mr. Schneiderman is also looking at whether private equity executives treated management fees as a return of invested capital — potentially escaping taxation entirely — or deferred payouts of the converted fees in ways that improperly reduced their tax liabilities.
Executives at three of the firms subpoenaed by Mr. Schneiderman, who asked for anonymity because they were bound by confidentiality agreements, said that disclosures to their investors clearly stated that the waived fees were allocated equally to all the investments in a fund.
The leaked documents show that Bain has in recent years waived management fees in at least eight private equity and other funds, including one formed as early as January 2002. The documents stated that Bain executives had the right to decide either annually or each quarter whether to waive some or all of their management fees; they also had the ability to convert the waived fees into investments in particular companies held by the funds.
Victor Fleischer, a law professor and finance expert at the University of Colorado who has been critical of the tax rules for private equity firms, said he believed Bain had waived management fees into investments with so little risk that the arrangement would not qualify for the capital gains rate if challenged by the I.R.S.
“There is a tension between economic risk and tax risk that is supposed to be inversely proportional,” Mr. Fleischer said. “The way Bain set it up there’s not much risk at all, so it’s hard to see how this income should receive capital gains treatment.”

Michael Luo contributed reporting.
Courtesy: New York Times
OxBridgeResearch

A123 Systems, AONE, Profile, Summary

A123 Systems |AONE | Profile | Summary

A123 Systems – AONE - develops and manufactures advanced Nanophosphate® lithium iron phosphate batteries and energy storage systems. The company’s technology enables customers to commercialize innovative products for the transportation, electric grid, commercial and government markets.

A123's proprietary Nanophosphate technology is built on novel nanoscale materials initially developed at the Massachusetts Institute of Technology. The company has spent more than $2 billion dollars on development and large scale manufacturing plants with global ambitions.
IronPhosphate Battery Technology
A123’s high-performance Nanophosphate® lithium iron phosphate (LiFePO4) battery technology delivers high power and energy density combined with excellent safety performance and extensive life cycling in a lighter weight, more compact package. Our products have low capacity loss and impedance growth over time, allowing our systems to meet end-of-life power and energy requirements with minimal pack oversizing.
Lithium Ion Battery Technology
A123’s next-generation Nanophosphate EXT™ lithium ion battery technology improves power capability at low temperature and life at high temperature, potentially reducing or eliminating the need for costly thermal management.
By extending the capabilities of our core Nanophosphate® technology over a wider temperature operating range, Nanophosphate EXT is expected to deliver increased performance and reliability while minimizing complexity and reducing total cost of ownership (TCO) over the life of the battery system for a number of applications, including micro hybrid vehicles, electric vehicles, telecommunications backup and military systems, among others.
Energy Storage Systems
A123 Systems excels at designing and manufacturing fully-integrated battery systems that help enable our customers to take new products from concept to commercialization. A123 has extensive engineering experience in developing and implementing advanced components, software, electronics, thermal management and battery management systems for innovations in battery system design. We provide complete system design and integration services and develop optimized systems that meet our customer’s performance requirements, including power, safety, life, and energy, while meeting size, weight and cost targets.
The Opportunity
The recession in the United States and European Economic crisis resulted in slower than expected demand for the Electric Vehicles. The company is poised to benefit when the global economic conditions improve, it has invested hundreds of millions in R&D and established long term relationships with leading OEMs and built a network of charging stations.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Hemispherx Biopharma, HEB, Profile, Summary

Hemispherx Biopharma | HEB | Profile | Summary
Hemispherx Biopharma (HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®.
Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in New Brunswick, New Jersey.

ALFERON
Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection.  Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.
Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.
ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.
Clinically Effective:
All warts disappeared in 54% of patients.3
No recurrence in 76% of complete responders at follow-up.3
Completely cleared 73% of all treated warts.3,4
No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
Provides a spectrum of multiple alpha interferon subtypes.1,

What's in the Pipeline?
Ampligen® (poly I:poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching.  Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza.

Watch This!
On July 31, 2012 Hemispherx submitted its complete response to the FDA’s Complete Response Letter in support of Ampligen®’s New Drug Application for Chronic Fatigue Syndrome (“CFS”).
Its too early to tell what the FDA's response would be, however, the response from investors has been very positive. We alerted our members and followers last week and we believe this company should be on your radar!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.